Strategic and Tactical Competitive Insights
We deliver crucial insights that empower clients to make winning strategic decisions.
Our consulting uncovers threats/opportunities, empowering clients to make strategic decisions that yield winning outcomes.
We deliver evidence-based recommendations, informed by expert interviews, to help clients address issues across:
- Asset Clinical Development and Commercialization
- R&D and Pipeline Assets
- Market Access
- Pricing/Reimbursement
- Regulatory Needs
- Emerging Markets
- Biosimilars/Generics
- OTC Offerings
- Digital Health
We provide decision support across the product lifecycle:
- New Product Planning
- Brand Planning
- Mature Product Planning
Our research capabilities are bolstered by in-house experts and a network spanning:
- Oncology/Hematology (solid/liquid tumors etc.)
- Gene and Cell Therapy / Rare Diseases (muscular dystrophy, ophthalmology, hemophilia etc.)
- Inflammatory and Autoimmune Diseases (including rheumatology, dermatology, allergy, MS etc.)
- Neurological Disorders (including epilepsy, Alzheimer’s, schizophrenia, PD etc.)
- Respiratory Disorders (including asthma, COPD, IPF, PAH etc.)
- Cardiovascular Disorders / Diabetes (including stroke, lipid disorders etc.)
- Infectious Diseases / Vaccines (including HIV, HCV, flu, MRSA, RSV etc.)
- Pain (including chronic pain, cancer-associated pain etc.)
- Blood Disorders (e.g. hemophilia)
With timely insights across therapy areas, we equip clients to accelerate competitive advantage.
Ready to build winning competitive strategies?
Let’s accelerate your success together. Contact us at info@lqventures.com.
October 14, 2025
Endocrinology Today : SMOC1 impact on T2D and more breakthroughs (Oct 7–14, 2025)
October 14, 2025
Lucid Diligence Brief: Excellergy ECRIs, $70M investment
October 13, 2025
Top Oncology News: Video summary (Sept 29 – Oct 13, 2025)
October 13, 2025
Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025)
October 13, 2025
Oncology Today: ADCs, PD-L1 & FDA Wins (Oct 6–13, 2025)
October 13, 2025
AI in Healthcare and Digital Health Today (Oct 6–13, 2025)
October 13, 2025
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI
October 11, 2025
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
October 10, 2025
Latest Public Health News – Sept 27th to Oct 10th
October 10, 2025